Related Experiment Video
Updated: Aug 5, 2026
11:52
Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
Published on: August 4, 2016
Optimizing bioinformatic workflows to extract clinically usable gene expression data from targeted tumor RNA
Xiaokang Pan1, Ashley Patton1, Yi Seok Chang1
1James Molecular Laboratory at Polaris, The Ohio State University Wexner Medical Center, Columbus, OH 43240, United States.
Bioinformatics Advances
|July 30, 2026
Summary
Targeted RNA sequencing panels can improve tumor classification using differential gene expression (DGE) analysis. Optimized methods for read counting and normalization enable robust DGE profiling from smaller gene sets.
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- Targeted RNA sequencing (RNA-seq) is crucial for detecting gene fusions in tumors.
- Clinical application of expression data from fusion panels in fusion-negative cases remains limited.
- Differential gene expression (DGE) profiling offers potential for enhanced tumor classification.
Purpose of the Study:
- To optimize methods for DGE profiling using targeted RNA-seq panels.
- To evaluate the efficacy of optimized pipelines for tumor classification.
- To compare DGE data from targeted panels with full RNA-seq.
Main Methods:
- Compared read counting tools, selecting featureCounts for speed and robustness.
- Evaluated five normalization strategies for DESeq2, identifying stable gene sets for optimal normalization.
- Assessed optimized pipeline using new targeted panels and compared results with full RNA-seq.
Main Results:
- FeatureCounts demonstrated superior performance in read counting for targeted panels.
- Optimal normalization using stably expressed genes improved DGE analysis.
- The optimized pipeline achieved comparable tumor clustering results to full RNA-seq.
Conclusions:
- An optimized DGE pipeline enhances the clinical utility of targeted RNA-seq panels.
- This approach facilitates improved tumor classification, even in fusion-negative cases.
- The findings support the use of targeted panels for robust gene expression analysis in oncology.
